Project Grant R01CA316157
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $601K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Newark, NJ 07107, USA
Similar Awards
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $651,545 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the meningeal lymphatic system as a pathogenic driver of chemotherapy-induced cognitive impairment in cancer survivors. The research targets chemobrain, a persistent cognitive dysfunction affecting pediatric and adult cancer survivors whose underlying mechanisms remain...
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $516,808 under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, to elucidate the mechanism of targeting methionine synthase (MTR) to enhance anti-tumor immunity in KRAS-driven lung cancer. The recipient will conduct research to understand how MTR targeting enhances immune responses in KRAS-driven non-small cell lung cancer (NSCLC), which exhibits...
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $599,978 under the Cancer Cause and Prevention Research program (CFDA 93.393) on July 1, 2026. The award funds a five-year prospective cohort study examining the relationship between perceived social obligations and clinical and patient-reported outcomes in 315 patients with advanced, poor-prognosis cancer. The research tests the hypothesis that higher patient-reported...
- The National Institute of Child Health and Human Development awarded Rutgers, The State University of New Jersey $432,421 on August 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to evaluate the protective efficacy and genomic stability of a checkpoint kinase 2 inhibitor (CK2II) against cyclophosphamide-induced gonadotoxicity in mouse and human ovarian follicles. The research addresses off-target damage to ovarian germ cells in female cancer...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded $457,683 to The Children's Hospital of Philadelphia on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize a macromolecular prodrug-based delivery strategy for the topoisomerase I inhibitor SN22 designed to overcome tumor defense mechanisms and suppress high-risk neuroblastoma, the most common and deadly solid tumor of childhood. The project targets...
- The National Institutes of Health's National Cancer Institute awarded $331,085.91 under the Cancer Research Manpower federal grant program (CFDA 93.398) to Brigham & Women's Hospital Inc. on February 1, 2021 for completion by September 30, 2022. The project grant funding will support research investigating the role of cellular senescence in chemotherapy-related cognitive impairment and the contribution of microglia to chemotherapy-induced senescence in the brain. Specifically, the grantee...
- The National Cancer Institute awarded the University of Rochester $814,967 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate trajectories of neurotoxicity among adolescents and young adults with Hodgkin lymphoma. The award funds research examining long-term neurotoxic effects of cancer therapy—including cancer-related cognitive impairment and peripheral and autonomic neuropathy—in this population despite the absence of central nervous...
- The National Cancer Institute awarded a cooperative agreement to Rutgers The State University of New Jersey for $975,000 on March 21, 2026, under the Cancer Treatment Research program (CFDA 93.395). The award funds clinical trial support infrastructure and operations for the Rutgers Cancer Institute and RWJBarnabas Health System across multiple hospital sites within the health system. The award supports a centralized research administration model through the Office of Human Research Services,...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $533,245 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop strategies to eradicate leukemia-initiating cells through investigation of protein glutathionylation regulation. The award supports research examining how post-translational modification of proteins through glutathionylation regulates oxidative phosphorylation in acute myeloid leukemia cells and leukemia-initiating cells,...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $399,829 to the University of Maryland, Baltimore on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop protein degradation strategies that overcome menin drug resistance in acute leukemias. The project addresses rapid drug resistance to menin inhibitors in clinical trials for MLL-rearranged (MLLR) leukemias, which carry a dismal prognosis...